Latest Commercial Rollouts News

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

Swift Networks has locked in key contracts with Australia's largest Aged Care provider and Chevron, while progressing its Swift TV rollout on track for Q3 FY26. The company also completed a $2.2 million capital raise, positioning itself for growth in new markets.

Sprintex has successfully delivered and begun commissioning integrated control systems for Mest Water’s Netherlands facility, marking a key milestone before commercial production scale-up and a potential €9.3 million maiden order.

Yojee Limited has successfully raised $5.4 million to accelerate the commercial rollout of its MOSAIC platform, which has now entered live customer beta testing in Australia. The company also expanded key contracts and strengthened its balance sheet with a robust cash position.

JAYRIDE Group Limited has secured $200,000 through the issuance of convertible notes, aiming to support its SaaS platform expansion and meet ASX requotation requirements. The raise includes participation from a sophisticated investor and a company director, with shareholder approval pending.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.

Firebrick Pharma has secured a $102,000 investment from its Philippines strategic partner, Pharma Nutria N.A., Inc., reinforcing its position ahead of the Nasodine nasal spray launch in 2026.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.